Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Large B-Cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05659628
What this trial is testing

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
Ningbo No. 1 Hospital 24
Not applicableNot Yet RecruitingNCT07669194
What this trial is testing

Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine 30
Early research (Phase 1)Looking for participantsNCT05836896
What this trial is testing

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

Who this might be right for
NeoplasmsRelapsed Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)+2 more
Technische Universität Dresden 16
Testing effectiveness (Phase 2)Ended earlyNCT05453396
What this trial is testing

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+5 more
University of Washington 11
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)UnknownNCT02758925
What this trial is testing

CyBeR Association in Relapsed/Refractory DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
University Hospital, Caen 78
Testing effectiveness (Phase 2)Ended earlyNCT05498220
What this trial is testing

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center 5
Testing effectiveness (Phase 2)Looking for participantsNCT06554600
What this trial is testing

Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Refractory or Relapsed Diffuse Large B Cell Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 36
Testing effectiveness (Phase 2)Study completedNCT03520920
What this trial is testing

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Who this might be right for
Marginal Zone LymphomaFollicular LymphomaDiffuse Large B-Cell Lymphoma
BeiGene 41
Early research (Phase 1)WithdrawnNCT03349346
What this trial is testing

Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Who this might be right for
Diffuse Large B-Cell LymphomaMediastinal B-cell Lymphoma
Gilead Sciences
Early research (Phase 1)Active Not RecruitingNCT05665062
What this trial is testing

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Who this might be right for
CLL/SLLNHLMantle Cell Lymphoma+4 more
Synthekine 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Large-scale testing (Phase 3)Study completedNCT01805557
What this trial is testing

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

Who this might be right for
Diffuse Large B-cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma Recurrent
Fondazione Italiana Linfomi - ETS 108
Early research (Phase 1)Study completedNCT00791011
What this trial is testing

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Who this might be right for
Hodgkin's LymphomaLow Grade LymphomaLymphoma+3 more
Amgen 33
Not applicableStudy completedNCT04150328
What this trial is testing

Lenalidomide Monotherapy in R/R DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
MorphoSys AG 490
Testing effectiveness (Phase 2)UnknownNCT05392257
What this trial is testing

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Who this might be right for
Overall Survival
Qingdao Central Hospital 20
Early research (Phase 1)Study completedNCT00005634
What this trial is testing

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Ended earlyNCT03103971
What this trial is testing

HuJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Adult Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+14 more
Fred Hutchinson Cancer Center 55
Early research (Phase 1)Ended earlyNCT01088763
What this trial is testing

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Who this might be right for
Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germinoma+43 more
National Cancer Institute (NCI) 129
Early research (Phase 1)WithdrawnNCT02532192
What this trial is testing

A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center
Next Page